Navigation Links
Mylan Announces XELODA® Settlement and License Agreement
Date:9/21/2011

PITTSBURGH, Sept. 21, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement and license agreement with Hoffman La Roche Inc. resolving litigation related to XELODA® Tablets, 150 mg and 500 mg, USP, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.

Pursuant to the agreement, the litigation was dismissed on Sept. 21, 2011.  Additional details are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. XELODA had U.S. sales of $570 million for the twelve months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the litigation settlement. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
2. Mylan Launches Generic Version of Uroxatral® Tablets
3. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
4. Mylan Launches First Generic Version of Entocort EC® Capsules
5. Mylan Receives Approval for Generic Version of Aricept® Tablets
6. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
7. Mylan Launches Generic Version of Roxicodone® Tablets
8. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
9. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
10. Mylan Launches First Generic Version of Amrix® Capsules
11. Mylan Launches Generic Version of Risperdal® M-Tab®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... IBM ) Research has today announced new research developments ... retina. The Melbourne based IBM researchers ... in retina images, which could in the future offer doctors ... who may be at risk of eye diseases – such ... world. The research began in 2015 and ...
(Date:2/21/2017)... , Feb. 21, 2017 Diabetic Shoes Market: Overview ... ... be described as a disease, which is marked by high ... and insulin action. The disease has become a global epidemic ... Diabetes affects several organs of the body including eyes, kidneys, ...
(Date:2/21/2017)... -- /PR Newswire/ -- UBM Medica,s Eye Care Group ( ... Modern Retina ( www.modernretina.com ), a new ... Built upon the success of Ophthalmology Times , ... in the areas of retinal surgery, clinical information, research, ... informational needs and filling existing educational gaps, Modern ...
Breaking Medicine Technology:
(Date:2/20/2017)... BROOK, Ill. (PRWEB) , ... February 20, 2017 ... ... potential to reduce the rate at which women are called back for additional ... the journal Radiology . , In 2011, the U.S. Food and Drug ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
(Date:2/20/2017)... ... February 20, 2017 , ... For Immediate Release, ... a leading provider of innovative software for connected home healthcare, today announced ... care journey management for home healthcare. , Built on Orbita Health ...
(Date:2/20/2017)... Yardley, PA (PRWEB) , ... February 20, 2017 , ... ... are collaborating to help health care providers better manage patient health risks, foster behavior ... largest medication video library in the world, will present a demonstration of its video ...
(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and IBM ... benefit for companies that want to help members of their workforce battling cancer. ... access to Watson’s suite of oncology offerings for insights on cancer treatment options, ...
Breaking Medicine News(10 mins):